Novel therapies for cyclic GMP control of vascular smooth muscle growth

American Journal of Therapeutics

Volumn 15, Issue 6, 2008, Pages 551-564

  Tulis, David A ^a,b  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BAY 41 2272; Carbon monoxide; Cyclic GMP; Heme oxygenase; Vascular smooth muscle; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; BAY 415843; CARBON MONOXIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GLYCERYL TRINITRATE; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE; NATRIURETIC FACTOR; NITRIC OXIDE; NITRIC OXIDE DONOR; ORGANIC NITRATE; PHOSPHODIESTERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

CARDIAC PATIENT; DRUG MECHANISM; ERECTILE DYSFUNCTION; HUMAN; MUSCLE GROWTH; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARBON MONOXIDE; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CELL PROLIFERATION; CYCLIC GMP; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HEME OXYGENASE (DECYCLIZING); HUMANS; INDAZOLES; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PYRAZOLES; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 57649133965     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318140052f     Document Type: Review

References (68)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:69-171.
2. Folkow B, Haeger K, Uvnas B. Cholinergic vasodilator nerves in the sympathetic outflow to the muscles of the hindlimb of the cat. Acta Physiol Scand. 1948;15:401-411.
3. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
4. Furchgott RF. Discovery of endothelium-derived relaxing factor and its identification as nitric oxide. In: Panza JA, Cannon RO III, eds. Endothelium, Nitric Oxide, and Atherosclerosis: From Basic Mechanisms to Clinical Implications. Armonk, NY: Futura Publishing Co, Inc; 1999:3-11.
5. Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep. 1999;19:235-251.
6. Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP. J Cyclic Nucleotide Protein Phosphor Res. 1983;9:281-296.
7. Martin W, Villani GM, Jothianandan D, et al. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther. 1985;232:708-716.
8. Ignarro LJ, Harbison RG, Wood KS, et al. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther. 1986;237:893-900.
9. Ignarro LJ, Byrns RE, Buga GM, et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacological and chemical properties that are identical to those of nitric oxide radical. Circ Res. 1987;61:866-879.
10. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
11. Loscalzo J, Vita JA, eds. Nitric Oxide and the Cardiovascular System. Totowa, NJ: Humana Press; 2000.
12. Panza JA, Cannon RO III, eds. Endothelium, Nitric Oxide, and Atherosclerosis: From Basic Mechanisms to Clinical Implications. Armonk, NY: Futura Publishing Co, Inc; 1999.
13. Chung SJ, Fung HL. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther. 1990;253:614-619.
14. Stewart DD. Remarkable tolerance to nitroglycerin. Phila Polyclin. 1888;6:43.
15. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
16. Parker JD. Therapy with nitrates: increasing evidence of vascular toxicity? J Am Coll Cardiol. 2003;42:1835-1837.
17. Davis KL, Martin E, Turko IV, et al. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol. 2001;41:203-236.
18. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrate: the good, the bad, and ugly. Am J Physiol. 1996;271:C1424-C1437.
19. Cary SP, Marletta MA. The case of CO signaling: why the jury is still out. J Clin Invest. 2001;107:1071-1073.
20. Hobbs AJ. Soluble guanylate cyclase: an old therapeutic target re-visited. Br J Pharmacol. 2002;136:637-640.
21. Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Rev. 2006;5:755-768.
22. Tulis DA. Salutary properties of YC-1 in the cardiovascular and hematological systems. Curr Med Chem. 2004;2:343-359.
23. Jackson EB Jr, Mukhopadhyay S, Tulis DA. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside. Curr Vasc Pharmacol. 2007;5:1-14.
24. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA. 1968;61:748-755.
25. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase: characterization of the enzyme. J Biol Chem. 1969;244:6388-6369.
26. Gopinathan V, Miller NJ, Milner, AD, et al. Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Lett. 1994;349:197-200.
27. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992;267:18148-18153.
28. Sjorstrand T. Endogenous formation of carbon monoxide in man under normal and pathophysiological conditions. Scand J Clin Lab Invest. 1949;1:201-214.
29. Sjostrand T. Endogenous formation of carbon monoxide; the CO concentration in the inspired and expired air of hospital patients. Acta Physiol Scand. 1951;22:137-141.
30. Durante W. Carbon monoxide and bile pigments: surprising mediators of vascular function. Vasc Med. 2002;7:195-202.
31. Durante W, Johnson FK, Johnson RA. Role of carbon monoxide in cardiovascular function. J Cell Mol Med. 2006;10:672-686.
32. Ryter SW, Morse D, Choi AM. Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease. Am J Respir Cell Mol Biol. 2007;36:175-182.
33. Mayer B, Koesling D. cGMP signalling beyond nitric oxide. Trends Pharmacol Sci. 2001;22:546-548.
34. Wedel B, Humbert P, Harteneck C, et al. Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc Natl Acad Sci USA. 1994;29:2592-2596.
35. Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 1996;15:6863-6868.
36. Stone JR, Marletta MA. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem Biol. 1998;5:255-261.
37. Sharma VS, Magde D. Activation of soluble guanylate cyclase by carbon monoxide and nitric oxide: a mechanistic model. Methods. 1999;19:494-505.
38. Deinum G, Stone JR, Babcock GT, et al. Binding of nitric oxide and carbon monoxide to soluble guanylate cyclase as observed with Resonance raman spectroscopy. Biochem. 1996;35:1540-1547.
39. Tulis DA, Durante W, Peyton KJ, et al. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun. 2000;279:646-652.
40. Duckers HJ, Boehm M, True AL, et al. Heme oxygense-1 protects against vascular constriction and proliferation. Nat Med. 2001;7:693-698.
41. Tulis DA, Durante W, Peyton KJ, et al. Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. Atherosclerosis. 2001;155:113-122.
42. Aizawa T, Ishizaka N, Taguchi J, et al. Balloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injured rat carotid artery. Biochem Biophys Res Commun. 1999;261:302-307.
43. Liu XM, Azam MA, Peyton KJ, et al. Butylated hydroxyanisole stimulates heme oxygenase-1 gene expression and inhibits neointima formation in rat arteries. Cardiovasc Res. 2007;74:169-179.
44. Tulis DA, Durante W, Liu XM, et al. Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation. 2001;104:2710-2715.
45. Hesheng O, Jun Y, Ligia T, et al. Role of endogenous carbon monoxide in neointimal formation induced by balloon-injury in rat aorta. Chin Med Sci J. 1999;14:41-45.
46. Togane Y, Morita T, Suematsu M, et al. Protective roles of endogenous carbon monoxide in neointimal development elicited by arterial injury. Am J Physiol Heart Circ Physiol. 2000;278:H623-H632.
47. Otterbein LE, Zuckerbraun BS, Haga M, et al. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med. 2003;9:183-190.
48. Raman KG, Barbato JE, Ifedigbo E, et al. Inhaled carbon monoxide inhibits intimai hyperplasia and provides added benefit with nitric oxide. J Vasc Surg. 2006;44:151-158.
49. Tulis DA, Keswani AN, Peyton KJ, et al. Local administration of carbon monoxide inhibits neointima formation in balloon injured rat carotid arteries. Cell Mol Biol. 2005;51:441-446.
50. Ko FN, Wu CC, Kuo SC, et al. YC-1, a novel activator of platelet guanylate cyclase. Blood. 1994;84:4226-4233.
51. Wu CC, Ko FN, Kuo SC, et al. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol. 1995;116:1973-978.
52. Chun YS, Yeo EJ, Park JW. Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett. 2004;207:1-7.
53. Russwurm M, Koesling D. Guanylyl cyclase: NO hits its target. Biochem Soc Symp. 2004;71:51-63.
54. Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol. 1998;53:123-127.
55. Lee YC, Martin F, Murad F. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc Natl Acad Sci USA. 2000;97:10763-10768.
56. Russwurm M, Mergia E, Mullershausen F, et al. Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol Chem. 2002;277:24883-24888.
57. Galle J, Zabel U, Hubner U, et al. Effects of the soluble guanylate cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol. 1999;127:195-203.
58. Tulis DA, Bohl Masters KS, Lipke EA, et al. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun. 2002;291:1014-1021.
59. Wu CH, Chang WC, Chang GY, et al. The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. J Pharmacol Sci. 2004;94:252-260.
60. Liu YN, Pan SL, Peng CY, et al. YC-1 [3-(5′-hydroxymethyl-2′- furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther. 2006;316:35-41.
61. Straub A, Stasch JP, Alonso-Alija C, et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett. 2001;11:781-784.
62. Straub A, Benet-Buchholz J, Frode R, et al. Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett. 2002;10:1711-1717.
63. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215.
64. Mullershausen F, Russwurm M, Friebe A, et al. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation. 2004;109:1711-1713.
65. Bischoff E, Stasch JP. Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition [Response]. Circulation. 2004;110:e320-e321.
66. Cornwell TL, Soff GA, Traynor AE, et al. Regulation of the expression of cyclic GMP-dependent protein kinase by cell density in vascular smooth muscle cells. J Vasc Res. 1994;31:330-337.
67. Bendeck MP, Zempo N, Clowes AW, et al. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
68. Mason DP, Kenagy RD, Hasenstab D, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res. 1999;85:179-185.